HVO Hvivo Plc

TIDMHVO

RNS Number : 0412K

hVIVO plc

06 April 2018

For immediate release 7.00am: 6 April 2018

HVIVO PLC

("hVIVO" or the "Company")

Notice of Preliminary Results

hVIVO plc (AIM: HVO) will announce its audited preliminary results for the year ended 31 December 2017 on Thursday, 19 April 2018.

For further information please contact:

 
 hVIVO plc                            +44 207 756 1300 
 Kym Denny (Chief Executive 
  Officer) 
 Graham Yeatman (Chief Financial 
  & Business Officer) 
 
 Media Enquiries                      +1 919 710 9658 
 Susan Flood 
 
 Numis Securities Limited              +44 207 260 1000 
 Michael Meade / Freddie Barnfield 
  (Nominated Adviser) 
 James Black / Michael Burke 
  (Corporate Broking) 
 
 FTI Consulting 
 Simon Conway / Victoria Foster 
  Mitchell (UK)                       +44 203 727 1000 
 

Notes to Editors:

About hVIVO plc

hVIVO plc ("hVIVO") is developing a pioneering human-based analytical platform to accelerate drug discovery and development in airways diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORUGUMPCUPRPPA

(END) Dow Jones Newswires

April 06, 2018 02:00 ET (06:00 GMT)

Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024

Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024